Business plan- bilingue theme bar

This business plan is made with the purpose of presenting it to potential investors in business rounds and/or venture capital funds proposed by the Government within its national development plan. A business oportunity regarding the creation of a theme bar in Bogota that encourages bilingualism is considered is this document. Said idea arises in the formation process of the Modern Languages major as ECCI University students. There is a law in Colombia, the 1014 2006, the Promotion of a Culture of Entrepreneurship ,that seeks to encourage the development of innovative business ideas that motivate the creation of companies to sustain the economy, from educational establishments. Entrepreneurship is a way of thinking, reasoning, and acting focused on opportunities, outlined with a global vision and carried out through a balanced leadership and the management of a calculated risk which result is the creation of value that benefits the company, the economy and society.Introduction Chapter 1: Precedents Chapter 2: The development of the bars in The US The implementation of Bars in Colombia The emergence of the Bars in Bogota Problem Statement Chapter 3: Business Idea Chapter 4: Economic object Location Organizational Structure Objectives Chapter 5: General objective Specific objectives Mission Vision Corporative Image The Brand Logo Slogan Technical Study Chapter 6: Facilities Administrative Installation Production Plant Legal Framework Chapter 7: Normativity for the implementation of bars in Bogota Rules of Functioning Rules of Local Functioning Sayco and Acinpro Local regulations of Chapinero Fiscal responsibility – Taxes Social Responsibility Marketing Study Chapter 8: Indirect competition Direct competition Variables Instrument of data collection Data Analysis Analysis Matrix SWOT Matrix SWOT Matrix of analysis Otton Bar SAS SWOT Matrix of analysis direct competition La Villa Marketing Strategy Market Segmentation Financial Analysis Chapter 9: Table of Assets Payroll Expenses Table General Expenses Chart Cost Table Investment Table Balance pointPregradoProfesional en Lenguas ModernasLenguas Moderna

Hereditary angioedema due to C1 inhibitor deficiency: real-world experience from the Icatibant Outcome Survey in Spain

Bradykinin; Hereditary angioedema; IcatibantBradicinina; Angioedema hereditario; IcatibantBradicinina; Angioedema hereditari; IcatibantBackground The Icatibant Outcome Survey (IOS) is an international registry monitoring the use of icatibant, a bradykinin B2 receptor antagonist indicated for the acute treatment of hereditary angioedema (HAE) attacks. Our goal was to assess disease characteristics and icatibant treatment outcomes in patients with HAE due to C1 inhibitor deficiency (HAE type 1 or 2 (HAE-1/2)) from Spain relative to other countries participating in IOS. Methods Descriptive retrospective analyses of data are reported from 10 centers in Spain vs 51 centers in 12 other participating countries (July 2009 to January 2019). Results No meaningful differences were identified between patients in Spain (n = 119) and patients across other countries (n = 907) regarding median age at symptom onset (15.0 vs 12.0 years) or diagnosis (22.3 vs 20.5 years). Overall HAE attack rates (total attacks/total years of follow-up) were 2.66 in Spain and 1.46 across other countries. Patients in Spain reported fewer severe/very severe HAE attacks before treatment (41.0% vs 45.9%; P < 0.0001) and, for icatibant-treated attacks, longer median time to treatment (2.9 vs 1.0 h), time to attack resolution (18.0 vs 5.5 h), and total attack duration (24.6 vs 8.0 h). Use of androgens for long-term prophylaxis was higher in Spain (51.2% vs 26.7%). Conclusion Patients with HAE-1/2 in Spain reported fewer severe/very severe attacks, administered icatibant later, and had longer-lasting attacks than did patients across other countries in IOS. These differences may indicate varying disease management practices (e.g., delayed icatibant treatment) and reporting. Efforts to raise awareness on the benefits of early on-demand treatment may be warranted.The Icatibant Outcome Survey is funded and supported by Shire International GmbH, a Takeda company, Zurich, Switzerland. Under direction of the authors, Alpa Parmar, PhD, CMPP, Latoya M. Mitchell, PhD, CMPP, and Sophia Shumyatsky, PharmD, CMPP, employees of Excel Medical Affairs, provided writing assistance for this manuscript. Editorial assistance in formatting, proofreading, and copyediting also was provided by Excel Medical Affairs. Takeda Development Center Americas, Inc. provided funding to Excel Medical Affairs, provided funding to Excel Medical Affairs for support in editing this manuscript. The interpretation of the data was made by the authors independently

Estado de salud y barreras en la atención de niños con defectos congénitos nacidos entre el 2011 y el 2017 en dos instituciones de salud de Cali

Introduction: Birth defects affect 2-3% of births contributing an important load to the causes of infant morbidity and mortality during the first five years of life. In Colombia, they are the second cause of infant mortality according to reports from the Departamento Administrativo Nacional de Estadística (DANE) 2011.Objective: To describe the state of health and barriers in the health care of children with congenital defects born between 2011 and 2017 in two institutions of Cali.Materials and methods: We conducted a descriptive cross-sectional observational study. We included babies born between January, 2011, and December, 2017, with at least one congenital defect who were followed up by telephone.Results: Out of 54,193 births during the period, 1,389 (2.56%) newborns had at least one congenital defect. All cases were classified according to the prognostic scale and 881 were included in the follow-up. The most frequent congenital defect was congenital cardiac malformation with 88 cases (9.99%), followed by malformation/defect of the kidney with 73 cases (8.29%), Down syndrome with 72 cases (8.17%), and testicular abnormalities with 56 cases (6.36%). Out of the 454 cases with effective follow-up, 161 (35.46%) of the caregivers stated that they had experienced at least one type of barrier during health care.Conclusion: Follow-up programs should be implemented for patients with birth defects to contribute to reducing morbidity and mortality.Introducción. Los defectos congénitos afectan entre el 2 y el 3 % de los recién nacidos, y son una carga importante entre las causas de morbilidad y mortalidad infantil en los primeros cinco años de vida. En Colombia, fueron la segunda causa de mortalidad infantil según los reportes del Departamento Administrativo Nacional de Estadística (DANE) para el 2011.Objetivo. Describir el estado de salud y las barreras en la atención de niños con defectos congénitos nacidos entre el 2011 y el 2017 en dos instituciones de salud de Cali.Materiales y métodos. Se hizo un estudio observacional descriptivo de corte transversal. Se incluyeron los nacidos entre enero de 2011 y diciembre de 2017 con, al menos, un defecto congénito, a quienes se les hizo seguimiento telefónico.Resultados. De 54.193 nacidos en el período analizado, 1.389 (2,56 %) tenían, por lo menos, un defecto congénito. Todos los casos se clasificaron según la escala de pronóstico y se incluyeron 881 en el seguimiento. El defecto congénito más frecuente fue la malformación congénita cardíaca, con 88 (9,99 %) casos; en segundo lugar, las malformaciones o defectos del riñón, con 73 (8,29 %) casos; en tercer lugar, el síndrome de Down, con 72 (8,17 %) casos, y en cuarto lugar, las anormalidades testiculares, con 56 (6,36 %). Ciento sesenta y uno (35,46 %) de los cuidadores de los 454 casos con seguimiento efectivo, manifestaron haber encontrado, por lo menos, un tipo de barrera en la atención.Conclusión. Se deben implementar programas de seguimiento de los pacientes con defectos congénitos, que contribuyan a disminuir la morbimortalidad

Four-state full Q-band phase shifter using smooth-ridged waveguides

A novel four-state full Q-band waveguide phase shifter based on smooth-ridged sections is presented. The waveguide structure combines differential 90° and 180° phase shifters, whose combination provides the four-phase states (0°, 90°, 180°, and 270°) by appropriately controlling a set of millimeter-wave switches. Each differential phase shifter is performed using an E-plane continuous profile ridge to reach the 90° or 180° phase shift, respectively. The phase shifter module provides outstanding performance covering the full Q-band (33-50 GHz) with average phase results of 93.5°, 182.8°, and 270.6°.This work was supported by the Spanish Ministry of Economy and Competitiveness through the Consolider-Ingenio 2010 Program under Grant CSD2010-00064 and Grant ESP2015-70646-C2-2-R

Adherence to Direct Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation: A Cross-National Comparison in Six European Countries (2008–2015)

Anticoagulants; Europe; Non valvular atrial fibrillationAnticoagulants; Europa; Fibril·lació auricular no valvularAnticoagulantes; Europa; Fibrilación auricular no valvularAims: To describe and compare the adherence to different direct oral anticoagulants (DOACs) in eight European databases representing six countries. Methods: Longitudinal drug utilization study of new users (≥18 years) of DOACs (dabigatran, rivaroxaban, apixaban) with a diagnosis of non-valvular atrial fibrillation (2008–2015). Adherence was examined by estimating persistence, switching, and discontinuation rates at 12 months. Primary non-adherence was estimated in BIFAP and SIDIAP databases. Results: The highest persistence rate was seen for apixaban in the CPRD database (81%) and the lowest for dabigatran in the Mondriaan database (22%). The switching rate for all DOACs ranged from 2.4 to 13.1% (Mondriaan and EGB databases, respectively). Dabigatran had the highest switching rate from 5.0 to 20.0% (Mondriaan and EGB databases, respectively). The discontinuation rate for all DOACs ranged from 16.0 to 63.9% (CPRD and Bavarian CD databases, respectively). Dabigatran had the highest rate of discontinuers, except in the Bavarian CD and AOK NORDWEST databases, ranging from 23.2 to 64.6% (CPRD and Mondriaan databases, respectively). Combined primary non-adherence for examined DOACs was 11.1% in BIFAP and 14.0% in SIDIAP. There were differences in population coverage and in the type of drug data source among the databases. Conclusion: Despite the differences in the characteristics of the databases and in demographic and baseline characteristics of the included population that could explain some of the observed discrepancies, we can observe a similar pattern throughout the databases. Apixaban was the DOAC with the highest persistence. Dabigatran had the highest proportion of discontinuers and switchers at 12 months in most databases (EMA/2015/27/PH).The project has received support from the European Medicines Agency under the Framework service contract (nr EMA/2015/27/PH) with regard to the reopening of competition no. 3. K. Janhsen (Witten/Herdecke University, Alfred-Herrhausen-Straße 50, 58448 Witten, Germany (UW/GH)) and A. Heeke (AOK NORDWEST, Kopenhagener Straße 1, 44269 Dortmund, Germany). R. Gerlach and M. Tauscher (National Association of Statutory Health Insurance Physicians of Bavaria, Elsenheimerstr. 39, MD-80687 Munich, Germany). The authors from the BIFAP database would like to acknowledge the excellent collaboration of the primary care general practitioners and pediatricians, and also the support of the regional governments to the database. This study is based in part on data from the ‘base de datos para la investigación Farmacoepidemiológica en Atención Primaria’ (BIFAP) fully financed by the Spanish Agency on Medicines and Medical Devices (AEMPS). The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the EMA (European Medicines Agency) or one of its committees or working parties, or AEMPS (Agencia Española de Medicamentos y Productos Sanitarios). The authors thank Alethea Charlton for her support reviewing and editing the English. The authors thank SIDIAP (Sistema d’informació per al Desenvolupament de Investigació en Atenció Primària) for providing the data with respect to CPRD, approval of the study protocol was granted by the Independent Scientific Advisory Committee of the Medicines and Healthcare Products Regulatory Agency (protocol 17_089R)

Indications related to antidepressant prescribing in the Nivel-PCD database and the SIDIAP database

Altres ajuts: Acord transformatiu CRUE-CSICAntidepressant drug consumption has increased, mainly in the elderly. This trend could be explained by the use for indications other than depression. We aimed to describe the indications related to antidepressant drug new users in two primary care settings

Synergism interaction between genetic polymorphisms in drug metabolizing enzymes and NSAIDs on upper gastrointestinal haemorrhage: a multicenter case-control study

Genetic variation; Non-steroidal anti-inflammatory drugs; Upper gastrointestinal haemorrhageVariació genètica; Fàrmacs antiinflamatoris no esteroides; Hemorràgia gastrointestinal superiorVariación genética; Medicamentos antiinflamatorios no esteroideos; Hemorragia gastrointestinal superiorBackground Interindividual genetic variations contribute to differences in patients’ response to drugs as well as to the development of certain disorders. Patients who use non-steroidal anti-inflammatory drugs (NSAIDs) may develop serious gastrointestinal disorders, mainly upper gastrointestinal haemorrhage (UGIH). Studies about the interaction between NSAIDs and genetic variations on the risk of UGIH are scarce. Therefore, we investigated the effect of 16 single nucleotide polymorphisms (SNPs) involved in drug metabolism on the risk of NSAIDs-induced UGIH. Materials and methods We conducted a multicenter case-control study of 326 cases and 748 controls. Participants were sub-grouped into four categories according to NSAID exposure and genetic profile. We estimated odds ratios (ORs) and their 95% confidence intervals (CI) using generalized linear mixed models for dependent binomial variables and then calculated the measures of interaction, synergism index (S), and relative excess risk due to interaction (RERI). We undertook stratified analyses by the type of NSAID (aspirin, non-aspirin). Results We observed an excess risk of UGIH due to an interaction between any NSAID, non-aspirin NSAIDs or aspirin and carrying certain SNPs. The greatest excess risk was observed for carriers of: rs2180314:C>G [any NSAID: S = 3.30 (95%CI: 1.24–8.80), RERI = 4.39 (95%CI: 0.70–8.07); non-aspirin NSAIDs: S = 3.42 (95%CI: 1.12–10.47), RERI = 3.97 (95%CI: 0.44–7.50)], and rs4809957:A>G [any NSAID: S = 2.11 (95%CI: 0.90–4.97), RERI = 3.46 (95%CI: −0.40–7.31)]. Aspirin use by carriers of rs6664:C>T is also associated with increased risk of UGIH [ORaspirin(+),wild-type: 2.22 (95%CI: 0.69–7.17) vs. ORaspirin(+),genetic-variation: 7.72 (95%CI: 2.75–21.68)], yet larger sample size is needed to confirm this observation. Conclusions The joint effect of the SNPs s2180314:C>G and rs4809957:A>G and NSAIDs are more than three times higher than the sum of their individual effects. Personalized prescriptions based on genotyping would permit a better weighing of risks and benefits from NSAID consumption.This study was supported by grants from: Carlos III Health Institute (P I12/02414, of the P E I+D+I 2012-2016); Fondo Europeo de Desarrollo Regional (FEDER); the Novartis, Pfizer and Dr Esteve pharmaceutical companies; the Health Research Fund/Fondo de Investigaciońn Sanitaria (P I021512, P I021364, P I020661, and P I021572); Ministry of Health & Consumer Affairs, Spain (SAF2002-04057); Galician Regional Authority, Spain (P GIDIT03P XIC20806P N); Department of Health of the Basque Country (03/11092 and 11/111103); Fundacion Vasca de innovacion e investigacion sanitarias (OSIBG19/002 and OSIBG18/105). The genotyping service was carried out at CEGEN-P RB3-ISCIII; Carlos III Health Institute and ERDF (P T17/0019, of the P E I+D+I 2013-2016). The funding sources do not have any role in the study design; data collection, analysis and interpretation; writing the manuscript; and in the decision to submit the article for publication

Discourses of Inclusion and Diversity among Educators of the Municipal Network of Early Childhood Education Schools in Vitoria-Gasteiz

[ES] En este artículo, se presenta un análisis de los discursos en torno a la inclusión compartidos por las educadoras de la Red Municipal de Escuelas Infantiles (RMEI) de Vitoria-Gasteiz a lo largo de las distintas fases de un proceso de investigación acción en que participaron para elaborar el documento base (DB) para su nuevo Proyecto Educativo (PE). El objetivo del artículo es analizar cualitativamente las actitudes y percepciones de las educadoras hacia la educación inclusiva y la diversidad, que emanan de los discursos compartidos en las reflexiones grupales. Los resultados del análisis muestran que en los discursos de las educadoras aparecen seis líneas temáticas relativas a la educación inclusiva y la diversidad: una escuela en la que prima la acogida y el acompañamiento; escuela para todas y todos; centrada en el desarrollo integral y personalizado de la niña o el niño; con espacios, materiales y tiempos pensados para los niños y las niñas; formada por un equipo educativo comprometido, coordinado y preparado para responder a la diversidad; y, finalmente, abierta a las familias y la comunidad. En la discusión se hace hincapié en la importancia de incluir estos aspectos en la formación inicial y permanente del profesorado.[EN] In this article, the analysis of the discourses around inclusion shared by the educators of the Municipal Network of Early Childhood Education Schools in Vitoria-Gasteiz is presented. The purpose of this article to make a qualitative analysis on the educators’ attitudes and perceptions, considering inclusive education and diversity, issued from the shared discourses during group reflections. Results show that six topics related to inclusive education and diversity emerge from teachers’ discourses: a school where welcoming and nurture are prioritized; school for all; focused on the child’s integral personalised development; with spaces, materials and time thought for the child; consisted of a committed and coordinated educational team prepared to respond to diversity; and, finally, open to families and the community. During the discussion, it is underlined the relevance of including these aspects in initial and in-service training

A multicenter case–control study of the effect of e-nos VNTR polymorphism on upper gastrointestinal hemorrhage in NSAID users

Gastroenterology; PharmacogeneticsGastroenterologia; FarmacogenèticaGastroenterología; FarmacogenéticaBleeding in non-steroidal anti-inflammatory drug (NSAID) users limited their prescription. This first multicenter full case–control study (325 cases and 744 controls), explored the association of e-NOS intron 4 variable number tandem repeat (VNTR) polymorphism with upper gastrointestinal hemorrhage (UGIH) in NSAID exposed and unexposed populations and assessed any interaction between this polymorphism and NSAIDs. NSAID users carrying e-NOS intron 4 wild type genotype or VNTR polymorphism have higher odds of UGIH than those unexposed to NSAIDs [Odds Ratio (OR): 6.62 (95% Confidence Interval (CI): 4.24, 10.36) and OR: 5.41 (95% CI 2.62, 11.51), respectively], with no effect modification from VNTR polymorphism-NSAIDs interaction [Relative Excess Risk due to Interaction (RERI): −1.35 (95% CI −5.73, 3.03); Synergism Index (S): 0.77 (95% CI 0.31, 1.94)]. Similar findings were obtained for aspirin exposure. Non-aspirin NSAID users who carry e-NOS intron 4 VNTR polymorphism have lower odds of UGIH [OR: 4.02 (95% CI 1.85, 8.75) than those users with wild type genotype [OR: 6.52 (95% CI 4.09, 10.38)]; though the interaction estimates are not statistically significant [RERI: −2.68 (95% CI −6.67, 1.31); S: 0.53 (95% CI 0.18, 1.55)]. This exploratory study suggests that the odds of UGIH in NSAID or aspirin users does not modify according to patient´s e-NOS intron 4 genotype.This work was supported by a grant from Instituto de Salud Carlos III [PI12/02414]/Plan Estatal de I + D + I 2012–2016; Fondo Europeo de Desarrollo Regional (FEDER); the Novartis, Pfizer and Dr Esteve pharmaceutical companies; the Health Research Fund/Fondo de Investigación Sanitaria [PI021512, PI021364, PI020661, PI021572]; Ministry of Health & Consumer Affairs, Spain [SAF2002-04057]; Galician Regional Authority, Spain [PGIDIT03PXIC20806PN]; Department of Health of the Basque Country [03/11092 and 11/111103]; and Fundacion vasca de innovacin e investigacin sanitarias [OSIBG19/002 and OSIBG18/105]. The genotyping service was carried out at CEGEN-PRB3-ISCIII; Instituto de Salud Carlos III and ERDF [PT17/0019, of the PE I + D + I 2013–2016]

Módulos de conmutación de fase de 4 estados en banda Q para radioastronomía

Two greater than 30% relative bandwidth phase shifters with four phase states are designed to be integrated in a radio astronomy receiver at Q-band. Two different circuit topologies are presented in order to fulfil requirements. The first circuit is based on planar structures and PIN diodes, while the second design is based on waveguide phase shifters and SPDT MMICs. The planar circuit consists of two 90º out-ofphase microwave phase-shifting branches which are combined by Wilkinson power dividers; each branch is composed of a 180º phase shifter and a band-pass filter. The waveguide solution is based on cascaded 180º and 90º individual phase shifters. Both designs have been manufactured and their experimental characterization have shown significant results, making them suitable for being part of a radio astronomy receiver.Este trabajo ha sido financiado por el Ministerio de Economía y Competitividad bajo el programa CONSOLIDER-INGENIO 2010 referencia CSD2010-00064